Predictive Risk Score for Acute Kidney Injury in Hematopoietic Stem Cell Transplant

Author:

Rodrigues Natacha1,Fragão-Marques Mariana2,Costa Cláudia1ORCID,Branco Carolina1ORCID,Marques Filipe1ORCID,Vasconcelos Pedro3,Martins Carlos3,Leite-Moreira Adelino2,Lopes José António1ORCID

Affiliation:

1. Division of Nephrology and Renal Transplantation, Centro Hospitalar Universitário Lisboa Norte, EPE, 1649-028 Lisboa, Portugal

2. UnIC@RISE, Department of Surgery and Physiology, Faculty of Medicine, University of Porto, 4099-002 Porto, Portugal

3. Division of Hematology, Centro Hospitalar Universitário Lisboa Norte, EPE, 1649-028 Lisboa, Portugal

Abstract

Hematopoietic stem cell transplant (HSCT) is an important treatment option for hematologic malignancies. Acute kidney injury (AKI) is a common complication in HSCTs and is related to worse outcomes. We aimed to create a predictive risk score for AKI in HSCT considering variables available at the time of the transplant. We performed a retrospective cohort study. AKI was defined by the KDIGO classification using creatinine and urinary output criteria. We used survival analysis with competing events. Continuous variables were dichotomized according to the Liu index. A multivariable analysis was performed with a backward stepwise regression. Harrel’s C-Statistic was used to evaluate the performance of the model. Points were attributed considering the nearest integer of two times each covariate’s hazard ratio. The Liu index was used to establish the optimal cut-off. We included 422 patients undergoing autologous (61.1%) or allogeneic (38.9%) HSCTs for multiple myeloma (33.9%), lymphoma (27.3%), and leukemia (38.8%). AKI cumulative incidence was 59.1%. Variables eligible for the final score were: hematopoietic cell transplant comorbidity index ≥2 (HR: 1.47, 95% CI: 1.08–2.006; p = 0.013), chronic kidney disease (HR: 2.10, 95% CI: 1.31–3.36; p = 0.002), lymphoma or leukemia (HR: 1.69, 95% CI: 1.26–2.25; p < 0.001) and platelet-to-lymphocyte ratio > 171.9 (HR: 1.43, 95% CI: 1.10–1.86; p = 0.008). This is the first predictive risk score for AKI in patients undergoing HSCTs and the first study where the platelet-to-lymphocyte ratio is independently associated with AKI.

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Reference35 articles.

1. Global Burden of Disease 2019 Cancer Collaboration (2022). Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019. JAMA Oncol., 8, 420–444.

2. The epidemiological landscape of multiple myeloma: A global cancer registry estimate of disease burden, risk factors, and temporal trends;Huang;Lancet Haematol.,2022

3. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms;Alaggio;Leukemia,2022

4. Immunosenescence: A key player in cancer development;Lian;J. Hematol. Oncol.,2020

5. HAEMACARE Working Group (2010). Incidence of hematologic malignancies in Europe by morphologic subtype: Results of the HAEMACARE project. Blood, 116, 3724–3734.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3